Outcome of diffuse large B-cell lymphoma in the united states has improved over time but racial disparities remain: Review of SEER data

Rami S. Komrokji, Najla H. Al Ali, M. S. Beg, Malek M. Safa, Dana Rollison, Mohamed Kharfan-Dabaja, Celeste Bello, Jennifer Cultrera, Lubomir Sokol, Javier Pinilla-Ibarz, Eduardo M. Sotomayor

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials. Patients and Methods: We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004. Results: We identified 59,728 patients (mean age, 63 years; 54.4% men, 86.7% white) and had staging information for 57%, including 30% early-stage (I/II) and 27% advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P <.005). For the period from 2000 to 2004, 4-year OS was 46%. Outcome was better in white patients than in black (47 months versus 29 months) (P =.001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years. Conclusion: The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.

Original languageEnglish (US)
Pages (from-to)257-260
Number of pages4
JournalClinical Lymphoma, Myeloma and Leukemia
Volume11
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Epidemiology
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Survival
Registries
Monoclonal Antibodies
Clinical Trials

Keywords

  • Diffuse large B-cell lymphoma
  • Non-Hodgkin lymphoma
  • SEER

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Cite this

Outcome of diffuse large B-cell lymphoma in the united states has improved over time but racial disparities remain : Review of SEER data. / Komrokji, Rami S.; Al Ali, Najla H.; Beg, M. S.; Safa, Malek M.; Rollison, Dana; Kharfan-Dabaja, Mohamed; Bello, Celeste; Cultrera, Jennifer; Sokol, Lubomir; Pinilla-Ibarz, Javier; Sotomayor, Eduardo M.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, No. 3, 06.2011, p. 257-260.

Research output: Contribution to journalArticle

Komrokji, RS, Al Ali, NH, Beg, MS, Safa, MM, Rollison, D, Kharfan-Dabaja, M, Bello, C, Cultrera, J, Sokol, L, Pinilla-Ibarz, J & Sotomayor, EM 2011, 'Outcome of diffuse large B-cell lymphoma in the united states has improved over time but racial disparities remain: Review of SEER data', Clinical Lymphoma, Myeloma and Leukemia, vol. 11, no. 3, pp. 257-260. https://doi.org/10.1016/j.clml.2011.03.012
Komrokji, Rami S. ; Al Ali, Najla H. ; Beg, M. S. ; Safa, Malek M. ; Rollison, Dana ; Kharfan-Dabaja, Mohamed ; Bello, Celeste ; Cultrera, Jennifer ; Sokol, Lubomir ; Pinilla-Ibarz, Javier ; Sotomayor, Eduardo M. / Outcome of diffuse large B-cell lymphoma in the united states has improved over time but racial disparities remain : Review of SEER data. In: Clinical Lymphoma, Myeloma and Leukemia. 2011 ; Vol. 11, No. 3. pp. 257-260.
@article{160b32de6efe458ba880b13e7feb7c93,
title = "Outcome of diffuse large B-cell lymphoma in the united states has improved over time but racial disparities remain: Review of SEER data",
abstract = "Background: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials. Patients and Methods: We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004. Results: We identified 59,728 patients (mean age, 63 years; 54.4{\%} men, 86.7{\%} white) and had staging information for 57{\%}, including 30{\%} early-stage (I/II) and 27{\%} advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P <.005). For the period from 2000 to 2004, 4-year OS was 46{\%}. Outcome was better in white patients than in black (47 months versus 29 months) (P =.001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years. Conclusion: The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.",
keywords = "Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma, SEER",
author = "Komrokji, {Rami S.} and {Al Ali}, {Najla H.} and Beg, {M. S.} and Safa, {Malek M.} and Dana Rollison and Mohamed Kharfan-Dabaja and Celeste Bello and Jennifer Cultrera and Lubomir Sokol and Javier Pinilla-Ibarz and Sotomayor, {Eduardo M.}",
year = "2011",
month = "6",
doi = "10.1016/j.clml.2011.03.012",
language = "English (US)",
volume = "11",
pages = "257--260",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - Outcome of diffuse large B-cell lymphoma in the united states has improved over time but racial disparities remain

T2 - Review of SEER data

AU - Komrokji, Rami S.

AU - Al Ali, Najla H.

AU - Beg, M. S.

AU - Safa, Malek M.

AU - Rollison, Dana

AU - Kharfan-Dabaja, Mohamed

AU - Bello, Celeste

AU - Cultrera, Jennifer

AU - Sokol, Lubomir

AU - Pinilla-Ibarz, Javier

AU - Sotomayor, Eduardo M.

PY - 2011/6

Y1 - 2011/6

N2 - Background: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials. Patients and Methods: We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004. Results: We identified 59,728 patients (mean age, 63 years; 54.4% men, 86.7% white) and had staging information for 57%, including 30% early-stage (I/II) and 27% advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P <.005). For the period from 2000 to 2004, 4-year OS was 46%. Outcome was better in white patients than in black (47 months versus 29 months) (P =.001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years. Conclusion: The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.

AB - Background: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials. Patients and Methods: We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004. Results: We identified 59,728 patients (mean age, 63 years; 54.4% men, 86.7% white) and had staging information for 57%, including 30% early-stage (I/II) and 27% advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P <.005). For the period from 2000 to 2004, 4-year OS was 46%. Outcome was better in white patients than in black (47 months versus 29 months) (P =.001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years. Conclusion: The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.

KW - Diffuse large B-cell lymphoma

KW - Non-Hodgkin lymphoma

KW - SEER

UR - http://www.scopus.com/inward/record.url?scp=80053375056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053375056&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2011.03.012

DO - 10.1016/j.clml.2011.03.012

M3 - Article

C2 - 21658652

AN - SCOPUS:80053375056

VL - 11

SP - 257

EP - 260

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 3

ER -